Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Protagonist Therapeutics, Inc

Get SEC filing alerts via email and in your feed for Protagonist Therapeutics, Inc

PTGX

Protagonist Therapeutics, Inc

About Protagonist Therapeutics, Inc

Protagonist Therapeutics is a biopharmaceutical company focused on discovering and developing peptide-based therapeutics for hematology, inflammatory, and immunomodulatory diseases. Its pipeline includes novel peptides like rusfertide for polycythemia vera and icotrokinra for psoriasis and other inflammatory conditions. The company leverages proprietary peptide technology to create oral and injectable drugs, collaborating with partners like Takeda and J&J to address unmet medical needs in chronic diseases.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Protagonist Therapeutics, Inc

1
1
Protagonist Therapeutics, Inc Protagonist Therapeutics Reports 99% Revenue Increase to $56.4 Million in Latest Quarter

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
Protagonist Therapeutics, Inc Protagonist Therapeutics Reports Significant Revenue Decline and Net Loss for Fiscal Year 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Protagonist Therapeutics, Inc Protagonist Therapeutics Reports Revenue Decline and Increased Operating Expenses in Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Protagonist Therapeutics, Inc Protagonist Therapeutics Reports Q2 2025 Financial Results with Increased License Revenue and Net Loss

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Protagonist Therapeutics, Inc Protagonist Therapeutics Reports 89% Revenue Decline and $11.7 Million Net Loss in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Protagonist Therapeutics, Inc Protagonist Therapeutics Reports Significant Revenue Growth and Profitability Turnaround in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments